16 results
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
20 Dec 23
Impel Pharmaceuticals Announces Filing Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
6:08am
as set forth in this Agreement.
(iv) Gender and Number. Any reference to gender shall include all genders, and words imparting the singular number
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
7 Sep 23
Entry into a Material Definitive Agreement
4:19pm
as the singular and vice versa;
(b) words importing gender include all genders;
-32-
(c) any reference to a Section, Annex, Schedule or Exhibit refers
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
21 Aug 23
Entry into a Material Definitive Agreement
8:33am
as well as the singular and vice versa;
(b)words importing gender include all genders;
(c)any reference to a Section, Annex, Schedule or Exhibit
PRE 14A
IMPLQ
Impel Pharmaceuticals Inc
14 Apr 23
Preliminary proxy
4:11pm
in Nasdaq Rule 5605(f).
Board Diversity Matrix
Total Number of Directors
Female
Male
Non-Binary
Did Not Disclose
Gender
Part I: Gender Identity
S-3
EX-4.4
swl2e
16 May 22
Shelf registration
4:49pm
DEF 14A
yi9lqkpcm
26 Apr 22
Definitive proxy
4:16pm
10-K
3ud0514ec
29 Mar 22
Annual report
5:09pm
424B4
ggwvxu qtu0icb4
10 Sep 21
Prospectus supplement with pricing info
4:01pm
DRS
86hn8 2s7yxssn577ri
25 Aug 21
Draft registration statement
12:00am
424B1
orc96tmvo6oko
23 Apr 21
Prospectus with pricing info
4:01pm
S-1
rbxaotd4 cb3s
2 Apr 21
IPO registration
3:04pm
DRS/A
hts6 sh57cth6qvb
23 Mar 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next